RESULTS FROM TWO PHASE 3 RANDOMIZED TRIALS OF ENOBOSARM, SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM), FOR THE PREVENTION AND TREATMENT OF MUSCLE WASTING IN NSCLC.

被引：0
|
作者：
Crawford, Jeffrey [1 ]
Prado, Carla M. M. [2 ]
Hancock, Michael L. [3 ]
Johnston, Mary A. [3 ]
Dalton, James T. [3 ]
Steiner, Mitchell S. [3 ]
机构：
[1] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA
[2] Florida State Univ, Tallahassee, FL 32306 USA
[3] Gtx Inc, Memphis, TN USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
muscle wasting; cachexia; NSCLC; enobosarm;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.11-026
引用
收藏
页码：S1199 / S1199
页数：1
相关论文
共 50 条
  • [31] Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine
    Doty, Erin Gautier
    Krege, John H.
    Jin, Leah
    Raskin, Joel
    Singh, Rashmi B. Halker
    Kalidas, Kavita
    CEPHALALGIA, 2019, 39 (12) : 1569 - 1576
  • [32] Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials
    Karsdal, M. A.
    Byrjalsen, I.
    Alexandersen, P.
    Bihlet, A.
    Andersen, J. R.
    Riis, B. J.
    Bay-Jensen, A. C.
    Christiansen, C.
    OSTEOARTHRITIS AND CARTILAGE, 2015, 23 (04) : 532 - 543
  • [33] Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials
    Stauffer, Virginia L.
    Wang, Shufang
    Voulgaropoulos, Menelaos
    Skljarevski, Vladimir
    Kovacik, Amy
    Aurora, Sheena K.
    HEADACHE, 2019, 59 (06): : 834 - 847
  • [34] A phase 1/2 study to evaluate the safety and efficacy of EP0062, an oral Selective Androgen Receptor Modulator (SARM), for the treatment of AR+/HER2-/ER+ advanced breast cancer
    Lim, Elgene
    Hamilton, Erika
    Palmieri, Carlo
    Arkenau, Hendrik-Tobias
    Brook, Sue
    Fisher, Geoff
    Mazur, Andrew
    CANCER RESEARCH, 2023, 83 (05)
  • [35] Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials
    Eder, Lihi
    Tony, Hans-Peter
    Odhav, Satish
    Galindez Agirregoikoa, Eva
    Korkosz, Mariusz
    Schwartzman, Sergio
    Sprabery, Aubrey Trevelin
    Gellett, Amanda M.
    Park, So Young
    Bertram, Clinton C.
    Ogdie, Alexis
    RHEUMATOLOGY AND THERAPY, 2022, 9 (03) : 919 - 933
  • [36] Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials
    Lihi Eder
    Hans-Peter Tony
    Satish Odhav
    Eva Galindez Agirregoikoa
    Mariusz Korkosz
    Sergio Schwartzman
    Aubrey Trevelin Sprabery
    Amanda M. Gellett
    So Young Park
    Clinton C. Bertram
    Alexis Ogdie
    Rheumatology and Therapy, 2022, 9 : 919 - 933
  • [37] Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials
    Bussel, James
    Arnold, Donald M.
    Grossbard, Elliot
    Mayer, Jiri
    Trelinski, Jacek
    Homenda, Wojciech
    Hellmann, Andrzej
    Windyga, Jerzy
    Sivcheva, Liliya
    Khalafallah, Alhossain A.
    Zaja, Francesco
    Cooper, Nichola
    Markovtsov, Vadim
    Zayed, Hany
    Duliege, Anne-Marie
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (07) : 921 - 930
  • [38] Tapinarof cream for the treatment of atopic dermatitis: Efficacy and safety results from two Japanese phase 3 trials
    Igarashi, Atsuyuki
    Tsuji, Gaku
    Fukasawa, Shuichi
    Murata, Ryusei
    Yamane, Satoshi
    JOURNAL OF DERMATOLOGY, 2024, 51 (11): : 1404 - 1413
  • [39] 2-Chloro-4-[[(1R,2R)-2-hydroxy-2-methyl-cyclopentyl]amino]-3-methyl-benzonitrile: A Transdermal Selective Androgen Receptor Modulator (SARM) for Muscle Atrophy
    Saeed, Ashraf
    Vaught, Grant M.
    Gavardinas, Kostas
    Matthews, Donald
    Green, Jonathan E.
    Losada, Pablo Garcia
    Bullock, Heather A.
    Calvert, Nathan A.
    Patel, Nita J.
    Sweetana, Stephanie A.
    Krishnan, Venkatesh
    Henck, Judith W.
    Luz, John G.
    Wang, Yong
    Jadhav, Prabhakar
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (02) : 750 - 755
  • [40] Tildrakizumab, a selective IL-23p19 antibody, in the treatment of chronic plaque psoriasis: Results from two randomised, controlled, phase 3 trials
    Sinclair, R.
    Reich, K.
    Papp, K.
    Tyring, S. S.
    Thaci, D.
    Cichanowitz, N.
    Blauvelt, A.
    Liu, K.
    Li, Q.
    La Rosa, C.
    Green, S. A.
    Kimball, A. B.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2017, 58 : 9 - 10
12345